The signal in peptide science, decoded weekly.
A focused, editorial read covering GLP-1s, healing peptides, longevity research, and the FDA actions reshaping the industry. Written for readers who want evidence, not marketing.
Free. Weekly. Unsubscribe with one click.
Common questions.
How often does it send?
Weekly, every Thursday morning. Plus the occasional breaking-news alert when a material FDA action or clinical-trial readout happens (capped at ~2 per month so we don't train you to ignore us).
What's inside each issue?
A short opening take from the editor, three summaries of new peptide research from the past week, a regulatory corner with any FDA or compounding-pharmacy updates, a reader question, and one clearly-labeled sponsor slot. Links go to primary sources, not affiliate redirects unless clearly marked.
Is it free?
Yes. The weekly issue is free forever. We may launch a paid tier later with deeper data access (COA purity database, vendor price tracking) — but the weekly editorial will always be free.
Will you sell my email?
No. We use your email only to send the newsletter. No ad-network sharing, no vendor lists, no cross-site tracking. See our privacy policy.
How do I unsubscribe?
One-click unsubscribe link in every issue. No re-confirm, no dark patterns. We hit unsubscribe-rate goals by writing issues worth keeping, not by making you fight for the exit.